Chronic pain management is an area of major clinical
importance. Multiple prevalent conditions in veterinary
species are associated with pain and disability and the
limitations of existing therapeutic options, especially in
cats, have resulted in significant unmet medical need. In
this white paper, Dr David Gearing of Nexvet and his team
review the outcomes from pre-clinical and clinical studies
of fully caninised and fully felinised anti-nerve growth
factor monolocal antibodies, which support the further
development of these therapies for chronic pain
management in their respective species.